Navigation Links
Warner Chilcott Announces Receipt of Paragraph IV Certification Notice
Date:6/28/2010

ARDEE, Ireland, June 28 /PRNewswire-FirstCall/ -- Warner Chilcott plc (Nasdaq: WCRX) announced today that it has received a Paragraph IV Certification Notice from Par Pharmaceutical, Inc. ("Par").  The Paragraph IV Certification Notice advises the Company of the filing of an Abbreviated New Drug Application (ANDA) by Par for a generic version of the Company's ASACOL 400 mg delayed release mesalamine product.

ASACOL 400 mg, which the Company markets and sells in the United States under a license from Medeva Pharma Suisse AG ("Medeva"), is used in the treatment of ulcerative colitis and is protected by Medeva's U.S. Patent Nos. 5,541,170 and 5,541,171, each of which expire in July 2013.

The Company is currently reviewing the details of the Paragraph IV Certification Notice from Par and continues to have full confidence in the intellectual property protecting its ASACOL 400 mg product.

The Company

Warner Chilcott is a leading specialty pharmaceutical company currently focused on the gastroenterology, women's healthcare, dermatology and urology segments of the North American and Western European pharmaceuticals markets.  The Company is a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of its products.  WCRX-F

Forward-Looking Statements

This press release contains forward-looking statements, including statements concerning our operations, our economic performance and financial condition, and our business plans and growth strategy and product development efforts. These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "may," "might," "will," "should," "estimate," "project," "plan," "anticipate," "expect," "intend," "outlook," "believe" and other similar expressions are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties.

The following represent some, but not necessarily all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by our forward-looking statements: our substantial indebtedness; competitive factors in the industry in which we operate (including the approval and introduction of generic or branded products that compete with our products); our ability to protect our intellectual property; a delay in qualifying our manufacturing facilities that produce our products or production or regulatory problems with either third party manufacturers upon whom we may rely for some of our products or our own manufacturing facilities; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; adverse outcomes in our outstanding litigation or an increase in the number of litigation matters to which we are subject; government regulation, including domestic and foreign health care reform, affecting the development, manufacture, marketing and sale of pharmaceutical products, including our ability and the ability of companies with whom we do business to obtain necessary regulatory approvals; our ability to manage the growth of our business by successfully identifying, developing, acquiring or licensing new products at favorable prices and marketing such new products; our ability to obtain regulatory approval and customer acceptance of new products, and continued customer acceptance of our existing products; changes in tax laws or interpretations that could increase our consolidated tax liabilities; our ability to realize the anticipated opportunities from our acquisition of the global branded prescription pharmaceuticals business of The Procter & Gamble Company; the other risks identified in our periodic filings including our Annual Report on Form 10-K for the year ended December 31, 2009, and from time-to-time in our public filings, financial statements and other investor communications.

We caution you that the foregoing list of important factors is not exclusive. In addition, in light of these risks and uncertainties, the matters referred to in our forward-looking statements may not occur. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as may be required by law.


'/>"/>
SOURCE Warner Chilcott plc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent
2. Dr. Mahdi B. Fawzi Joins Warner Chilcott as President, Global Research and Development
3. Warner Chilcott Completes Acquisition of P&Gs Global Branded Prescription Pharmaceuticals Business
4. Warner Chilcott Announces 2010 Financial Guidance Conference Call
5. Warner Chilcott Announces Secondary Equity Offering
6. Warner Chilcott Announces Early Tender Results and Receipt of Consents from a Majority of Holders of its 8-3/4% Senior Subordinated Notes due 2015
7. Warner Chilcott Prices Secondary Equity Offering
8. Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015
9. Warner Chilcott Considers Potential Repurchase or Redemption of 8.75% Senior Subordinated Notes
10. Warner Chilcott Announces Earnings Release Date and Conference Call For First Quarter 2010 Financial Results
11. Warner Chilcott to Present at the Bank of America Merrill Lynch Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ) today ... effective Aug. 7, 2017. ... interests and will serve as president emeritus during a planned, ... in multiple leadership roles since he joined Diplomat with the ... provided decisive, strategic leadership which continues to benefit our patients ...
(Date:8/4/2017)... The search for test results that can ... has long been the goal of healthcare providers and ... the largest meeting of lab professionals and IVD firms ... firm Kalorama Information.  The firm said scores of companies ... supplies and software were at the American Association for ...
(Date:8/2/2017)... Fenita J. Caldwell is ... Lifetime Professional in the Field of Healthcare. Caldwell ... Pharmaceuticals, AG. Her skills and areas of expertise ... Fenita ... experience as a highly successful sales specialist in ...
Breaking Medicine Technology:
(Date:8/18/2017)... (PRWEB) , ... August 18, ... ... d/b/a Quick International, LLC (“Quick”), a highly specialized asset-light logistics provider of ... entered into a definitive agreement to purchase Unitrans International Corporation, a division ...
(Date:8/18/2017)... NY (PRWEB) , ... August 18, 2017 , ... ... of “Vision & Hearing” campaign, advocating for active, healthy lifestyles and highlighting the ... available for individuals with hearing impairments and shares the latest innovations in hearing ...
(Date:8/18/2017)... McLean, VA (PRWEB) , ... August 18, 2017 ... ... offers asset protection services and financial consultations to communities throughout the greater DC ... Semper K9 with the goal of rescuing local animals and training them to ...
(Date:8/18/2017)... ... August 18, 2017 , ... MLM Insurance Group, a Miami ... southern Florida, is working to support the Take Stock In Children Foundation during ... families. , The Take Stock In Children Foundation (TSC) offers guidance and assistance ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Golseth Agency, a Texas based insurance management ... spearheading a regional charity campaign organized to provide support to Christina Upchurch and her ... year, Christina and her children returned from out of town to find her husband ...
Breaking Medicine News(10 mins):